Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …

Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Atrial fibrillation (AF) is associated with significant morbidity and mortality related to stroke
due to thromboembolism. Several novel oral anticoagulants (NOACs) have been developed …

In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists
reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations …

Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …

Background Antithrombotic therapy reduces stroke, embolism and mortality in patients with
atrial fibrillation (AF); however, meta-analyses have focused on pairwise comparisons of …